跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2018-001337-41-PL
EUCTR2018-001337-41-PL进行中（未招募）1 期

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures

SK Life Science, Inc.0 个研究点目标入组 170 人开始时间: 2018年11月19日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
进行中（未招募）
入组人数
170
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1. Subject is male or female and aged =12 years.
  • •2. Written informed consent signed by the subject, or legal guardian, or legally authorized representative (LAR) prior to entering the study, in accordance with the International Council for Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines. If the
  • •written informed consent is provided by the legal guardian because the
  • •subject is unable to do so, a written or verbal assent from the subject
  • •must also be obtained. As required by country-specific regulations, only
  • •the subject may sign the ICF in accordance with ICH guidelines.
  • •3. Female subjects of childbearing potential are willing to use an acceptable
  • •form of birth control
  • •4. Subject has a clinical diagnosis of PGTC seizures (with or without other
  • •subtypes of generalized seizures) in the setting of idiopathic generalized
  • •5. Subject experiences at least 5 PGTC seizures in 12 weeks during the
  • •Pre-Randomization Period.
  • •6. Subject has had a routine electroencephalogram (EEG) within 5 years
  • •prior to Visit 1 (Screening/Baseline) or during the Pre-Randomization
  • •Period with electroencephalographic features consistent with idiopathic
  • •generalized epilepsy; other concomitant anomalies must be explained by
  • •adequate past medical history.
  • •7. Subject has undergone computed tomography (CT) or magnetic
  • •resonance imaging (MRI) within 10 years prior to Visit 1
  • •(Screening/Baseline) or during the Pre-Randomization Period that ruled
  • •out a progressive cause of epilepsy.
  • •8. Subject is currently receiving 1 to a maximum of 3 concomitant
  • •antiepileptic drugs (AEDs) with fixed dosing regimens for a minimum
  • •of 30 days prior to Visit 1 (Screening/Baseline).
  • •a) Benzodiazepines (except diazepam, see Exclusion Criterion No. 7)
  • •taken at least once per week during the 30 days prior to Visit 1
  • •(Screening/Baseline) for epilepsy, anxiety, or sleep disorder will be
  • •counted as 1 AED and the dosage must be continued unchanged
  • •throughout the study. Therefore, only a maximum of 2 additional
  • •approved AEDs will be allowed. (See Exclusion Criterion No. 10
  • •for intermittent benzodiazepine rescue parameters.)
  • •b) Subjects receiving felbamate as a concomitant AED must meet the
  • •following criteria:
  • •i. Have a 2-year history of felbamate use and a history of a fixed
  • •dosing regimen for a minimum of 60 days prior to Visit 1
  • •(Screening/Baseline).
  • •ii. No prior or known history of hepatotoxicity or hematologic
  • •disorder due to felbamate.
  • •9. Subject with an implanted vagal nerve or deep brain stimulator will be
  • •allowed if the stimulator was implanted at least 5 months prior to Visit 1
  • •(Screening/Baseline) and the stimulator parameters are not changed for
  • •30 days prior to Visit 1 and for the duration of the study.
  • •10. Subject taking a ketogenic diet will be allowed as long as the diet has
  • •been stable for at least 3 months prior to Visit 1 (Screening/Baseline)
  • •and will remain stable for the duration of the study.
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 34
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 126
  • •F.1.3 Elderly (>=65 years) yes
  • 另有 1 项未显示

排除标准

  • •1. Female subjects who are pregnant (or planning to become pregnant
  • •during the study), lactating, or breast-feeding.
  • •2. Subject has a history of status epilepticus that required hospitalization
  • •within 12 months prior to Visit 1 (Screening/Baseline).
  • •3. Subject has PGTC seizure clusters where individual seizures cannot be
  • •counted or classified.
  • •4. Subject has a history of non-epileptic psychogenic seizures.
  • •5. Subject has a concomitant diagnosis of partial onset seizure (POS).
  • •6. Subject has a clinical diagnosis of Lennox-Gastaut syndrome.
  • •7. Subject is currently taking (within the 30 days prior to Visit 1
  • •[Screening/Baseline]) any of the following medications: diazepam (for
  • •any reason other than as intermittent benzodiazepine rescue medication),
  • •phenytoin, mephenytoin, fosphenytoin, phenobarbital, primidone,
  • •ethotoin, clopidogrel, fluvoxamine, amitriptyline, clomipramine,
  • •bupropion, methadone, ifosfamide, cyclophosphamide, or efavirenz.
  • •8. Subject has participated in previous cenobamate clinical studies.
  • •9. Subject has a history of vigabatrin use within 5 months prior to Visit 1
  • •(Screening/Baseline), or the subject plans to begin treatment with
  • •vigabatrin during the study.
  • •a) A subject with a history of vigabatrin use that ended more than
  • •5 months prior to Visit 1 may be enrolled after documented evidence
  • •of no vigabatrin-associated clinically significant abnormality in an
  • •automated visual perimetry test.
  • •10. Subject has a history of intermittent use of rescue benzodiazepines (i.e.,
  • •1 to 2 doses over a 24-hour period is considered a 1-time rescue) 4 or
  • •more times within the 30 days prior to Visit 1 (Screening/Baseline).
  • •11. Subject has received an investigational drug or device within 30 days
  • •prior to Visit 1 (Screening/Baseline).
  • •12. Subject has a history of drug or alcohol dependency or abuse within
  • •2 years prior to Visit 1 (Screening/Baseline).
  • •13. Subject tests positive, via urine drug screen at Visit 1
  • •(Screening/Baseline), for illicit drugs not legalized in your region/state (e.g., tetrahydrocannabinol,
  • •amphetamines) or for a drug that has not been prescribed (e.g., certain
  • •14. Subject has a history of any serious drug-induced hypersensitivity
  • •reaction (including, but not limited to, Stevens Johnson syndrome, toxic epidermal necrolysis, or Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]) or any drug-related rash requiring hospitalization.
  • •15. History of AED-associated rash that involved conjunctiva or mucosae.
  • •16. History of more than one non-serious drug-related hypersensitivity
  • •reaction that required discontinuation of the medication.
  • •17. Subject has evidence of clinically significant abnormalities or disease
  • •(e.g., psychiatric, cardiac, respiratory, gastrointestinal, hepatic [AST or
  • •ALT more than 2 times the upper limit of normal (ULN), or total or
  • •direct bilirubin more than ULN], or renal disease) that, in the opinion
  • •of the Principal Investigator, could affect the subject’s safety or conduct
  • •of the study.
  • •18. Presence of congenital short QT syndrome or relevant replicated change
  • •in QT/QTc interval less than 340 msec on ECG.
  • •19. Subject has any significant active central nervous system (CNS)
  • •infection, demyelinating disease, degenerative neurologic disease or any
  • •CNS disease deemed to be progressive during the course of the study
  • •that may confound the interpretation of the study results.
  • 另有 3 项未显示

研究者

相似试验

进行中（未招募）
1 期
A Study to Evaluate Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive MedicatioMedDRA version: 20.0Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersHypertension
EUCTR2021-003776-13-EEAlnylam Pharmaceuticals, Inc.1,800
进行中（未招募）
1 期
A multicenter study to evaluate the safety, tolerability and efficacy of XEN1101 as additional therapy to standard treatment in focal epilepsy with an open-label extension.Adult focal (partial onset) epilepsyMedDRA version: 21.1Level: LLTClassification code 10065337Term: Focal epilepsySystem Organ Class: 100000004852
EUCTR2018-003221-29-ITXenon Pharmaceuticals Inc.300
招募中
1 期
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Properties of iN1011-N17 after Oral Administration in Healthy Volunteers and Post-Herpetic Neuralgia (PHN) PatientsPost Hepatic NeuralgiaInflammatory and Immune System - Other inflammatory or immune system disorders
ACTRN12622001300763iN Therapeutics Co., Ltd.32
招募中
3 期
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive CrisesPatients with a diagnosis of sicke cell disease who have experienced between 2 and 10 vaso-occlusive crises in the 12 months preceding enrollment and have been hospitalized for an index vaso-occlusive crises.SCD, vaso-occlusive crisis, blood disorders, hemoglobin, red blood cells, sickle-like shape, mutation in hemoglobin gene, sickle-cell trait, sickle-cell crisis, Sickle Cell Disease SCD, Hydroxyurea/ Hydroxycarbamide Therapy, SCA
LBCTR2021074831Global Blood Therapeutics, Inc.280
终止
3 期
Study of monotherapy Rapastinel in patients with Major Depressive Disorder (MDD)
JPRN-jRCT2080224073Allergan Japan K.K.690